Sangel Capital

Established in 2010, Sangel Capital is one of China's earliest healthcare-focused venture capital firms, specializing in investments within the life science and technology sectors. The firm is dedicated to supporting innovative enterprises in biomedicine, medical devices, and digital health, aiming to foster groundbreaking solutions in these fields. With a team comprising entrepreneurs, scientists, and industry professionals, Sangel Capital manages a series of RMB and USD funds, reflecting its commitment to both domestic and international markets.

Sangel Capital's investment strategy emphasizes identifying startups with high return potential and assisting them in reaching their full growth potential. The firm has a broad geographical presence, with offices in Shenzhen, Beijing, Suzhou, and Chicago, enabling it to tap into diverse markets and opportunities. This extensive network allows Sangel Capital to leverage a wide range of expertise and resources, enhancing its ability to support portfolio companies effectively.

Over the years, Sangel Capital has built a strong track record in the healthcare venture capital space, earning multiple awards from national organizations. Its portfolio includes notable companies such as Huaheng Biotech, Sirnaomics Ltd, 3D-Medicines, InnerMed, Yinyi Biotech, Ascentawits Pharmaceuticals, and Magpie Pharmaceuticals. These investments underscore the firm's focus on fostering innovation and addressing unmet medical needs through strategic partnerships and funding.